SCHEMBL14020184

SCHEMBL14020184

NCCN(C1CCNCC1)S(=O)(=O)c1ccc(Nc2nccc(Nc3cc(F)c(F)cc3F)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.48
CDK4 P11802 2/20 0.48
CCNE1 P24864 1/20 0.48
CA2 P00918 5/20 0.42
CA1 P00915 4/20 0.42
AURKA O14965 4/20 0.40
AURKB Q96GD4 2/20 0.40
CCNK O75909 1/20 0.40
CDK13 Q14004 1/20 0.40
CDK12 Q9NYV4 1/20 0.40
IKBKB O14920 1/20 0.39
CHUK O15111 1/20 0.39
KDR P35968 1/20 0.38
CCNA2 P20248 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KCNH2 Q12809 1/20 0.38
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14020182 0.91 IKBKB (0.47) CDK2CDK4CCNE1CA2CA1
SCHEMBL14020157 0.90 MEN1 (0.49) CDK2CDK4CCNE1CA2CA1
Hydrochloric Acid SCHEMBL4882044 0.89 MEN1 (0.48) CDK2CDK4CCNE1CA2CA1
SCHEMBL4623096 0.87 CDK2 (0.47) CDK2CDK4CCNE1CA2CA1
SCHEMBL4622465 0.87 CA2 (0.43) CDK2CDK4CCNE1CA2CA1
Hydrochloric Acid SCHEMBL4880400 0.86 CA2 (0.42) CDK2CDK4CCNE1CA2CA1
SCHEMBL4621289 0.84 MEN1 (0.47) CDK2CDK4CCNE1CA2CA1
Hydrochloric Acid SCHEMBL4884778 0.84 MEN1 (0.47) CDK2CDK4CCNE1CA2CA1
SCHEMBL14624774 0.83 MEN1 (0.46) CDK2CDK4CCNE1CA2CA1
SCHEMBL4623424 0.83 MEN1 (0.46) CDK2CDK4CCNE1CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed
WO-2007006926-A2 NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE CDK2 9/4885CDK4 54/4885CCNE1 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.